Manjistha for Anti-Inflammatory

Research suggests that Manjistha (Rubia cordifolia) demonstrates consistent anti-inflammatory activity across a range of preclinical studies, with multiple identified compounds — including purpurin, mollugin, and cyclopeptide RA-V — shown to reduce key inflammatory markers such as IL-1β, TNF-α, and IL-6, and to inhibit signaling pathways including NF-κB, NLRP3 inflammasome, and IL-6/JAK2/STAT3. Studies indicate these effects have been observed in models of arthritis, ulcerative colitis, intestinal inflammation, and myocardial injury, suggesting broad anti-inflammatory potential across tissue types. The available evidence base consists predominantly of in vitro cell studies and animal experiments, supported by several narrative reviews; one study examined a multi-herb Ayurvedic formulation containing Manjistha rather than isolating its effects, and no randomized controlled trials in humans were identified among the reviewed literature. While the direction of findings is uniformly supportive, the absence of clinical human trials and noted gaps in pharmacokinetic and safety data mean that the translation of these findings to human health applications remains an open question.